NeoLumina bio
About Us
Our Mission
We aim to design psychedelic-inspired therapeutics that offer greater predictability and control to increase effectiveness in treating mental health disorders.
With the rapidly rising global prevalence of eating disorders, anxiety and depression, and other mental health disorders, one of our goals is to develop effective treatments based on psilocybin and psilocin that remove the psychedelic effects; but have greater efficacy and fewer harmful side-effects than current drugs on the market.
Our first product candidate, a proprietary psilocybin-based oral capsule, is being prepared to enter human trials for eating disorders and our novel psilocybin and psilocin analogs will be eligible for patenting which would establish a valuable intellectual property portfolio.
Product Development
Advance our lead psilocybin-based product candidate to human studies
Continue proprietary natural molecule production and development
In partnership with Catalent, NeoLumina is ready to develop a proprietary psilocin drug with Catalent which enhances its ability to create effective treatments for mental health conditions while optimizing dosing and patient outcomes
Initial Areas of Focus
Our 4 initial areas of focus have been strategically selected as they offer the greatest market reach and potential impact.
EATING DISORDERS (ANOREXIA, BULIMIA, BINGE EATING)
- Eating disorders represent the deadliest of all mental health disorders (Current Psychiatry Reports, 2020)
- There are currently few drugs available to use for eating disorders
- It is estimated that 9% of the global population suffers from an eating disorder, so approximately 700 million people globablly and almost 30 million people in the US (National Association of Anorexia Nervosa and Associated Disorders)
Led by Dr. Wendy Oliver-Pyatt, MD – Director, International Association of Eating Disorder Professionals
Depression, Anxiety, Post Traumatic Stress Disorder (PTSD)
- Approximately 700 million to 1 billion people globally suffer from anxiety, depression, and/or PTSD
- Current drug treatments have limited efficacy and several negative side effects
Led by Dr. Mark Gold, MD – Distinguished Professor, Psychiatry, University of Florida
Alcohol and Drug Addiction
- Affects approximately 300 million people worldwide annually
- Only 10% of people addicted receive treatment
Led by Dr. Kevin Hill, MD – Addiction psychiatrist, Director of the Division of Addiction Psychiatry at Harvard’s Beth Israel Deaconess Medical Center, and an Associate Professor of Psychiatry at Harvard Medical School.
Pain
- Approximately 800 million people globally suffer from chronic pain
- More than 80% of patients with chronic pain are affected by severe depression
Led by Dr. Eduardo Muñoz, MD, PhD – Professor, Immunology, University of Córdoba
Learn More About Our Strategic Partners
We’ve strategically partnered with global experts in drug development
Partnership with Catalent
NeoLumina’s collaboration with Catalent aims to leverage proprietary technology and Catalent’s expertise in drug delivery to develop a first-in-class psilocin delivery product, capable of providing consistent, pre-determined doses of the active compound derived from psilocybin, intended for the treatment of various mental health disorders.
